Akron Biotech

18 articles about Akron Biotech

• Akron Bio Receives Eligibility Confirmation from PMDA in Japan for the Commercialization of Virus Inactivated Human Fibronectin in Clinical Cell Therapy Manufacturing

  1/17/2023

  Akron Bio (“Akron”), a leading supplier of critical inputs for cell and gene therapies, today announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has granted Akron Eligibility Confirmation for its cGMP Virus Inactivated Human Fibronectin.

• Akron Bio Appoints Christopher Murphy as Chief Executive Officer

  12/12/2022

  Akron Bio today announced the appointment of Christopher Murphy as Chief Executive Officer.

• Akron Bio Expands Commercialization of Advanced Gene Therapy and Vaccine Production with New Manufacturing Facility

  4/13/2022

  Akron Bio, a leading developer and manufacturer of critical building blocks used by biopharma to produce advanced therapies for the prevention and treatment of cardiovascular diseases and cancers, launched a new, state-of-the-art cGMP plasmid DNA manufacturing facility in Sarasota, Florida.

• Akron Biotech Signs Agreement With Synairgen plc to Supply Interferon-beta for COVID-19 Treatment

  10/19/2020

  Akron Biotechnology announced it has signed an agreement with Synairgen plc for the provision of SNG001, Synairgen’s wholly-owned inhaled interferon beta therapeutic candidate for the treatment of COVID-19 patients.

• Akron Biotech Submits eCTD Drug Master Files with FDA for Its Suite of cGMP Immunotherapy Cytokines

  7/13/2020

  Akron Biotechnology, which develops and manufactures cGMP-compliant cytokines and other ancillary materials to enable cell and gene therapy development and commercialization, today announced that it has submitted Type II Drug Master Files (DMF

• 

  In Other (Biopharma) News: Non-Coronavirus Stories this Week

  3/31/2020

  The following is a roundup of some of this week's non-coronavirus biopharma news.

• Akron Biotech Expands to Second US Manufacturing Facility

  3/30/2020

  New Site in Sarasota, FL, Increases Akron’s US Manufacturing Capacity for Cell and Gene Therapy Materials and Technologies

• Akron Biotechnology publishes industry-wide recommendations for ATMP ancillary material regulation

  1/22/2020

  Paper published in "Cytotherapy" to propose framework for critical standardization of ATMP material regulation

• Arcline Investment Management Acquires Majority Interest In Cell And Gene Therapy Materials Supplier Akron Biotechnology

  9/11/2019

  Arcline Investment Management announced that it has acquired a majority interest in Akron Biotechnology LLC.

• Akron Biotech Submits eCTD Drug Master File for IL-2 with the FDA

  2/13/2019

  Akron Biotechnology, a leading supplier of ancillary materials to the regenerative medicine industry, announces that it has filed a Drug Master File (DMF) Type II for its Interleukin-2 (IL-2) in Electronic Common Technical Document (eCTD) format with the U.S. Food and Drug Administration (FDA). 

• Akron Biotechnology, LLC Release: Company Partners In New Manufacturing USA Institute

  1/25/2017

• Akron Biotechnology, LLC Named 2014 Florida Companies To Watch Winner

  8/19/2014

• Cryoprinting Red Blood Cells: Akron Biotechnology, LLC And Stanford University Collaborative Study

  8/11/2014

• Akron Biotechnology, LLC Awarded SBIR Grant For Development Of Novel Method To Isolate Adipose Derived Stem Cells

  4/14/2014

• Akron Biotechnology, LLC Relationship with Israeli Incubator, Targetech, Shows Promise

  5/19/2011

• Akron Biotechnology, LLC Merging with AppliChem GmbH, a Leading BioChemicals Manufacturer

  3/3/2009

• Akron Biotechnology, LLC Announces the Launch of: CryoSolve – A Single-Use cGMP Cell Cryopreservation Media

  1/29/2009

• Akron Biotechnology, LLC Partners with Austin Chemical Company, Inc. for US B2B Distribution

  1/7/2009